Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Nintedanib 4x25 mg vs 1x100 mg in Healthy Males
NCT04938453Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve from 0 to Last Quantifiable Data Point and Maximum Measured Concentration. Started Jul 2021; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04938453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938453.